Technology Appraisal Virtual Committee Meeting

Committee B

Zoom

# Minutes: Confirmed

## Date and Time: Wednesday 14 October 2020 09:00am - 3:55pm

### Present:

1. Professor Amanda Adler (Chair) Present for all notes
2. Dr Sanjeev Patel (Vice-Chair) Present for all notes
3. Dr Carlo Berti Present for all notes
4. Dr Laura Bojke Present for topic 1 to 9
5. Dr Mark Glover Present for all notes
6. Dr Megan John Present for all notes
7. Professor Sanjay Kinra Present for all notes
8. Dr Nicholas Latimer Present for topic 1 to 9
9. Dr Veline L'Esperance Present for all notes
10. Dr Rhiannon Owen Present for all notes
11. Ms Anna Pracz Present for all notes
12. Dr Stephen Smith Present for all notes
13. Professor Nicky Welton Present for all notes
14. Mr Nigel Westwood Present for all notes
15. Mr Peter Wheatley Price Present for notes 1 to 8
16. Professor Sarah Wild Present for all notes
17. Dr Ed Wilson Present for all notes
18. Dr Stuart Williams Present for all notes
19. Mr Tony Wootton Present for all notes

### In attendance:

* Helen Knight, Programme Director, NICE, Present for notes 9
* Nicole Elliott, Associate Director, NICE, Present for all notes
* Ross Dent, Associate Director, NICE, Present for notes topic 1 to 9
* Joanne Ekeledo, Project Manager, NICE, Present for all notes
* Laura Marsden, Coordinator, NICE, Present for all notes
* Gemma Smith, Coordinator, NICE, Present for notes 1 to 8
* Sophie McHugh, Administrator, NICE, Present for notes topic 9 to 15
* George Braileanu, Technical Analyst, NICE, Present for notes 1 to 8
* Lorna Dunning, Technical Adviser, NICE, Present for notes 10 to 15
* Jessica Cronshaw, Technical Analyst, NICE, Present for notes 10 to 15
* Mary Hughes, Technical Adviser, NICE, Present for notes 9
* Miriam Brazzelli, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Dwayne Boyers, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Elisabet Jacobsen, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Neil Scott, Aberdeen HTA Group, Evidence Review Group, Present for notes 1 to 4
* Yen-Fu Chen, Warwick Evidence, Evidence Review Group, Present for notes 10 to 12
* Ewen Cummins, Warwick Evidence, Evidence Review Group, Present for notes 10 to 12
* Mubarak Patel, Warwick Evidence, Evidence Review Group, Present for notes 10 to 12
* Charlotte Bradbury, Clinical Expert, Consultant Haematologist, Present for notes 1 to 4
* Quentin Hill, Clinical Expert, Consultant Haematologist, Present for notes 1 to 4
* Rhonda Anderson, Patient Expert, Volunteer Patient Mentor, Present for notes 1 to 4
* Derek Elston, Patient Expert, Trustee for ITP Support Association, Present for notes 1 to 4
* Prof Peter Clark, Cancer drugs Fund Clinical Lead, Present for notes 10 to 15

### Non-public attendees:

* Philippe Alipat, Evidence Synthesis Analyst, NIHR Innovation Observatory, Present for notes 1 to 4 and 10 to 12
* Harry Atkins, Coordinator, NICE International, Present for notes 1 to 4 and 10 to 12
* Helen Barnett, Editor, NICE, Present for notes 1 to 8
* Sarah Blagden, Public Health Specialty Registrar, NICE, Present for notes 10 to 15
* Annabelle Borromeo, Health Technology Assessment Council Philippines, Present for notes 1 to 4 and 10 to 12
* Linford Briant, Sir Henry Wellcome Postdoctoral Fellow, University of Oxford, Present for notes 1 to 4 and 10 to 12
* Ruth Coleman, Senior Research Statistician, University of Oxford, Present for notes 1 to 4 and 10 to 12
* Henry Edwards, Associate Director, NICE, Present for notes 1 to 8
* Ann Greenwood, Editor, NICE, Present for notes 10 to 15
* Melissa Guerrero, Department of Health (Philippines) HTA Unit, Present for notes 1 to 4 and 10 to 12
* Aleli Kraft, Health Technology Assessment Council Philippines, Present for notes 1 to 4 and 10 to 12
* Heidi Livingstone, Public Involvement adviser, NICE, Present for notes 1 to 4
* Ella Livingstone, Commercial Risk Assessment Technical Adviser, NICE, Present for notes 10 to 15
* Catherine Manuela, Health Technology Assessment Council Philippines, Present for notes 1 to 4 and 10 to 12
* Cecilia Maramba-Lazarte, Health Technology Assessment Council Philippines, Present for notes 1 to 4 and 10 to 12
* Edgar Masanga, Business Analyst, NICE, Present for all notes
* Rosalee Mason, Corporate Office Coordinator, NICE, Present for all notes
* Marita Reyes, Health Technology Assessment Council Philippines, Present for notes 1 to 4 and 10 to 12
* Natalie Spray, CCT, NICE, Present for all notes
* Rebecca Thomas, Assistant Technical Analyst, NICE, Present for notes 1 to 4 and 10 to 12
* Georgina Wilkins, NHRI Observer, Present for notes 1 to 4 and 10 to 12

## Notes

### Any other Business

1. None.

### Minutes from the last meeting

1. The committee approved the minutes of the committee meeting held on Wednesday 9 September 2020.

## Appraisal of fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

### Part 1 – Open session

1. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Grifols (fostamatinib).
2. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests

	1. Prior to the meeting Peter Wheatley Price declared a potential financial interest as he is employed by Takeda who manufacture several preparations of both IV and SC immunglobin which are indicated for immunodeficiency syndromes with impaired antibody production.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	2. Dr Quentin Hill declared a direct financial interest as he received a fee for participating in an advisory board for Grifols in September 2019. He also declared a direct non-financial interest as he is a named author on several abstracts published at academic conferences relating to data from the fostamatinib studies. Quentin also holds research grants from the ITP support association and Alexion pharmaceuticals. He currently participates in an external data monitoring committee for a clinical trial (non-ITP) for Pfizer. Previously he has received speaker or advisory fees from Alexion, Amgen, Apellis, Bioverativ, Novartis and Shire.
		1. It was agreed that this declaration would not prevent him from participating in this section of the meeting.
	3. No further conflicts of interest were declared for this appraisal.
	4. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	5. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

1. The committee discussed confidential information submitted as part of this appraisal.
2. Agreement on the content of the Appraisal Consultation Document (ACD) discussed by the committee.
3. The committee decision was based on consensus.
4. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

## Appraisal of caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

### Part 2 – Closed session only

1. The Chair asked all committee members and NICE staff present to declare any relevant interests.
	1. No conflicts of interest were declared for this appraisal.
	2. The Chair introduced the lead team who gave presentations on the clinical effectiveness and cost effectiveness of the treatment.
	3. The committee discussed confidential information submitted as part of this appraisal.
	4. Agreement on the content of the Final Appraisal Determination (FAD) was discussed by the committee.
	5. The committee decision was based on consensus.
	6. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

## Appraisal of encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer [ID1598]

### Part 1 – Open session

1. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests.
	1. Prior to the meeting Nicholas Latimer declared a direct financial interest as he has done consultancy work for Pierre Fabre on this topic.
	2. It was agreed that this declaration would prevent him from participating in this section of the meeting and he therefore remained absent.
	3. No further conflicts of interest were declared for this appraisal.
2. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.
3. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

### Part 2 – Closed session (company representatives, clinical and patient experts, ERG/AG representatives were asked to leave the meeting)

1. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
2. The committee decision was based on consensus.
3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.